Lundbeck CEO eyes deals to bolster pipeline, complement growth drivers ahead of patent losses

Lundbeck CEO eyes deals to bolster pipeline, complement growth drivers ahead of patent losses

Source: 
Fierce Pharma
snippet: 

Lundbeck’s Charl van Zyl has about 100 days under his belt as the company’s new CEO. For the next 100 days and beyond, the chief exec is buckling down on his efforts to sustain the company's growth trajectory through upcoming patent cliffs.